Press Releases

Date Title and Summary
Nov 09, 2022

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million , a 59.3% YoY Increase Company Increases Full Year 2022 Total Revenue Guidance to $205-210 Million Q3 2022 GAAP Net Income of $22.7 Million ( $0.22 per basic and $0.20 per diluted share), which Includes a One Time Charge of $4.1 Million
Nov 07, 2022

Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

CORAL GABLES, Fla. , Nov. 07, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it
Oct 25, 2022

Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022

Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET CORAL GABLES, Fla. , Oct. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel
Sep 29, 2022

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients

FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S. CORAL GABLES, Fla. , Sept. 29, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and
Sep 09, 2022

Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

CORAL GABLES, Fla. , Sept. 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that
Aug 24, 2022

Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference

CORAL GABLES, Fla. , Aug. 24, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced
Aug 09, 2022

Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update

Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53.0 Million , a 57.7% YoY Increase Cash and Short-Term Investments at June 30, 2022 were $220.8 Million , with No Funded Debt Completed Acquisition of Ruzurgi® U.S. and Mexico Commercial Rights Advanced Plans to Diversify Portfolio and
Jul 26, 2022

Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022

The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET CORAL GABLES, Fla. , July 26, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and
Jul 12, 2022

Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical

As Part of the Settlement, Catalyst has Acquired Certain of Jacobus’ Intellectual Property Rights, Including the U.S. and Mexico Rights to Ruzurgi® CORAL GABLES, Fla. , July 12, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage
May 17, 2022

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

CORAL GABLES, Fla. , May 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that

Displaying 1 - 10 of 24